Company / Net Income
IGC Pharma, Inc. Net Income History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Net Income
-$7.1M
FY2025
5-year range
-$15.0M / -$7.1M
FY2021-FY2025
Trend
+38.1%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Improved from -$15M to -$7M over the past 2 years.
Based on SEC 10-K filings.
-$7M in FY2025.
Improved from -$15M to -$7M over the past 2 years.
Net Income over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Key checks
Key Insights
- In FY2025, net income increased 38.1% year-over-year.
- Peak net income was recorded in FY2019.
- Lowest net income in the period was in FY2023.
Company context
Key Data Points
- Altman Z-Score -13.04 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Net IncomeValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | -$7.1M | +38.1% |
| FY2024 | -$11.5M | +23.4% |
| FY2023 | -$15.0M | -70.4% |
| FY2022 | -$8.8M | -20.5% |
| FY2021 | -$7.3M | -78.5% |
| FY2020 | -$4.1M | -129.4% |
| FY2019 | -$1.8M | +4.4% |
| FY2018 | -$1.9M | +33.5% |
| FY2017 | -$2.8M | +39.1% |
| FY2016 | -$4.6M | -52.7% |
As of FY2025 · SEC 10-K · Updated Jun 24, 2026